Omnicell, Inc. (NASDAQ:OMCL) Shares Bought by Graham Capital Management L.P.

Graham Capital Management L.P. raised its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 75.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,102 shares of the company's stock after buying an additional 15,963 shares during the period. Graham Capital Management L.P. owned approximately 0.08% of Omnicell worth $1,652,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Smartleaf Asset Management LLC grew its holdings in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares during the period. Summit Investment Advisors Inc. raised its stake in Omnicell by 6.9% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock worth $213,000 after purchasing an additional 307 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares during the period. Finally, Redmond Asset Management LLC raised its position in shares of Omnicell by 0.3% in the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company's stock worth $5,396,000 after buying an additional 371 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on OMCL. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a research report on Saturday, May 3rd. Wells Fargo & Company upgraded Omnicell from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $31.00 to $35.00 in a report on Wednesday. Benchmark dropped their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Omnicell presently has a consensus rating of "Hold" and an average target price of $46.50.

Omnicell Stock Down 2.3%

NASDAQ OMCL traded down $0.65 on Thursday, reaching $28.08. The company had a trading volume of 764,960 shares, compared to its average volume of 557,913. The firm has a market capitalization of $1.32 billion, a PE ratio of 104.00, a P/E/G ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The firm has a 50-day moving average of $31.73 and a 200-day moving average of $39.72.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. The firm had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Omnicell's revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the company posted $0.03 earnings per share. On average, equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.